Clinical trials
HSV clinical trials
Below are recruiting hsv clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06741982RecruitingPhase 1
Immune-targeted therapy and virus treatment before head and neck cancer surgery
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–70 - NCT03911388RecruitingPhase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Birmingham, AlabamaAges 3–22 - NCT01913106RecruitingPhase 1/Phase 2
Testing valacyclovir with an added cancer gene in prostate radiation
This Phase 1/2 study tests whether adding a cancer-targeting gene therapy (HSV-tk) and the antiviral medicine valacyclovir to brachytherapy can better treat recurrent prostate cancer in the prostate area. It may help by making cancer cells more vulnerable to the treatment.
Houston, TexasAges Any age - NCT05477849RecruitingPhase 1
Study drug for people with advanced solid tumors
This Phase 1 trial tests the safety and early effects of VG2025 in people with advanced solid cancers that have stopped responding to standard treatments. It’s mainly looking for side effects and how the body processes the drug, and it may offer a new option when other treatments haven’t worked.
Hangzhou, ZhejiangAges 18–75 - NCT06746480RecruitingPhase 2
Study of VG161 for advanced bile duct cancer
This trial tests a new medicine called VG161 for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that has stopped responding to or could not be tolerated after at least one prior treatment. It is given by injection into the tumor, and the study wants to see if it can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–75 - NCT06474442RecruitingPhase 2
BD111 gene therapy for herpes simplex virus eye infection
This trial tests a new gene therapy called BD111 for people with a herpes simplex virus infection in the cornea (the clear front part of the eye). It aims to see if the treatment is safe and can help clear the virus, possibly improving vision.
Wenzhou, ZhejiangAges 18–70 - NCT07262164RecruitingPhase 1
Testing VG2062 for advanced solid tumors
This trial is testing a new drug called VG2062 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how the body processes it.
HebeiAges 18–75 - NCT06134492RecruitingPhase 3
Acyclovir for pneumonia patients with HSV-1 on breathing support
This trial tests whether acyclovir, an antiviral drug, can help patients with pneumonia who are on breathing support and have herpes simplex virus in their lung fluid. The goal is to see if it improves recovery.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT03596086RecruitingPhase 1/Phase 2
Study drug plus radiation and chemo for recurrent brain cancer
This Phase 1/2 study tests whether combining an HSV-tk “gene switch” treatment, valacyclovir tablets, focused radiation (SBRT), and chemotherapy can help people with recurrent glioblastoma or anaplastic astrocytoma. It may help shrink tumors or slow growth after standard treatments have already been tried.
Houston, TexasAges 18 years+ - NCT03603405RecruitingPhase 1/Phase 2
Test vaccine and radiation with chemotherapy for new brain tumor
This trial studies a gene-based treatment (HSV-tk) given with radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. It may help the new brain tumor respond better to standard treatments, though risks and benefits are still being tested.
Houston, TexasAges 18 years+ - NCT04806464RecruitingPhase 1
Study drug injection for advanced liver cancer
This Phase 1 trial tests VG161, a study medicine, given by injection into liver or nearby tumors for people with advanced primary liver cancer that has not responded to standard treatment (or there is no standard option). The goal is to find a safe dose and see how the tumors respond.
Hangzhou, ZhejiangAges 18–75 - NCT06008925RecruitingPhase 1/Phase 2
VG161 plus nivolumab for advanced gastric cancer
This trial tests a new combination therapy (VG161, a herpes-based virus therapy, plus nivolumab) for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two previous treatments, including a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT06126510RecruitingPhase 2
Study of VG161 for advanced bone and soft tissue sarcoma
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
BeijingAges 18–75 - NCT07076498RecruitingPhase 1
Gene therapy for children and adults with diffuse midline glioma
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
Houston, TexasAges 3 years+ - NCT01011712Recruiting
Study immune causes of severe viral infections
This study looks at why some people have severe or unusual viral infections, even when they do not have a known immune problem. It collects blood and tissue samples to better understand possible inherited immune issues and may help future diagnosis and treatment.
Bethesda, MarylandAges 2–100 - NCT07330440Enrolling by invitationPhase 1
MRNA vaccine study for preventing genital herpes
This study tests a new mRNA vaccine designed to protect against herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes. It is for healthy adults who have not had a genital herpes outbreak in the last 6 months.
BeijingAges 18–55
Hear when a new HSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hsv?
- Yes. Clin2 currently lists 16 recruiting hsv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hsv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hsv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.